Supporters of PEPFAR argue that failing to reauthorize the program would risk the leadership role the U.S. currently holds in implementing HIV/AIDS prevention initiatives around the world.
As the 2024 election looms, will we see a health policy pause?
The presidential election will dampen the prospects for major health legislation in 2024. But that doesn’t mean debate over abortion or drug pricing will subside.
Analyzing ‘march-in rights’: Will Biden seize the reins on drug costs?
Long thought to have been a settled issue among Democrats and even some Republicans, Trump has once again brought back the old debate around Obamacare.
FDA adopts Operation Warp Speed lessons for rare disease pilot program
The FDA announced the launch of a pilot program, dubbed START, to address challenges associated with rare disease development and speed up the regulatory process.
Is the VA starting to embrace psychedelic-assisted therapy for mental health?
The House Committee on Veterans’ Affairs’ Subcommittee on Health held what appears to be its first official hearing on the use of psychedelic therapies for veterans’ mental health care.
FTC to crack down on ‘sham patents’ in FDA’s Orange Book
The Better Mental Health Care, Lower-Cost Drugs, and Extenders Act would boost mental health services as well as target PBMs and their role in high drug prices.
What does Biden’s executive order to regulate AI mean for healthcare?